

Amendment to the Specification:

Please replace the Abstract with the following amended Abstract:

ABSTRACT OF THE DISCLOSURE

Compounds of formula I disclosed herein are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

